Moderate Renal Function Impairment Does Not Affect Outcomes of Reduced-Intensity Conditioning with Fludarabine and Melphalan for Allogeneic Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 9, 2009, Pages 1094-1099

  de Souza, Jonas A ^a,b   Saliba, Rima M ^a   Patah, Poliana ^c   Rondon, Gabriela ^a   Ribeiro, Rachel ^a   de Padua Silva, Leandro ^a   Qazilbash, Muzaffar H ^a   Hosing, Chitra ^a   Popat, Uday ^a   Efebera, Yvonne ^a   Champlin, Richard E ^a   de Lima, Marcos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c HOSPITAL SÍRIO LIBANÊS   (Brazil)

Author keywords

Creatinine; Reduced intensity; Renal function; Toxicity; Transplantation

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; COTRIMOXAZOLE; CREATININE; FLUDARABINE; FOSCARNET; GANCICLOVIR; GENTAMICIN; MELPHALAN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY; VALACICLOVIR; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HLA MATCHING; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION TEST; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; REDUCED INTENSITY CONDITIONING;

ADULT; AGED; GLOMERULAR FILTRATION RATE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY FAILURE, ACUTE; LEUKEMIA, MYELOID, ACUTE; MALE; MELPHALAN; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; VIDARABINE; YOUNG ADULT;

EID: 67849090854     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.05.006     Document Type: Article

References (22)

1. Schrier R.W., and Parikh C.R. Comparison of renal injury in myeloablative autologous, myeloablative allogeneic and non-myeloablative allogeneic haematopoietic cell transplantation. Nephrol Dial Transplant 20 (2005) 678-683
2. Parikh C.R., and Coca S.G. Acute renal failure in hematopoietic cell transplantation. Kidney Int 69 (2006) 430-435
3. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
4. Champlin R., Khouri I., Shimoni A., et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 111 (2000) 18-29
5. Giralt S., Khouri I., and Champlin R. Non myeloablative "mini transplants.". Cancer Treat Res 101 (1999) 97-108
6. Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97 (2001) 631-637
7. de Lima M., Anagnostopoulos A., Munsell M., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104 (2004) 865-872
8. Martino R., Caballero M.D., Simon J.A., et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100 (2002) 2243-2245
9. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105 (2005) 1810-1814
10. Valcarcel D., Martino R., Sureda A., et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 74 (2005) 144-151
11. Shimoni A., Hardan I., Shem-Tov N., et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 20 (2006) 322-328
12. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis (2002) S1-S266 39(2 Suppl. 1)
13. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
14. Bearman S.I., Appelbaum F.R., Buckner C.D., et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6 (1988) 1562-1568
15. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005) 2912-2919
16. Parikh C.R., Yarlagadda S.G., Storer B., Sorror M., Storb R., and Sandmaier B. Impact of acute kidney injury on long-term mortality after nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant 14 (2008) 309-315
17. Parikh C.R., Sandmaier B.M., Storb R.F., et al. Acute renal failure after nonmyeloablative hematopoietic cell transplantation. J Am Soc Nephrol 15 (2004) 1868-1876
18. Kersting S., Dorp S.V., Theobald M., and Verdonck L.F. Acute renal failure after nonmyeloablative stem cell transplantation in adults. Biol Blood Marrow Transplant 14 (2008) 125-131
19. Weiss A.S., Sandmaier B.M., Storer B., Storb R., McSweeney P.A., and Parikh C.R. Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. Am J Transplant 6 (2006) 89-94
20. Kersting S., and Verdonck L.F. Successful outcome after nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with renal dysfunction. Biol Blood Marrow Transplant 14 (2008) 1312-1316
21. Hingorani S., Guthrie K.A., Schoch G., Weiss N.S., and McDonald G.B. Chronic kidney disease in long-term survivors of hematopoietic cell transplant. Bone Marrow Transplant 39 (2007) 223-229
22. Parikh C.R., Schrier R.W., Storer B., et al. Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. Am J Kidney Dis 45 (2005) 502-509